The FDA new deputy commissioner roles 2026 plan could bring a major change to the leadership structure of the U.S. Food and Drug Administration. According to a Reuters report citing CNBC, the U.S. Department of Health and Human Services (HHS) is planning two new deputy commissioner positions—one focused on technology, healthcare and artificial intelligence (AI), and another focused on drugs.
The appointments have not been formally announced, and no final decisions have been made. Jared Seehafer is reportedly the leading candidate for the technology-focused position, while the candidate for the drugs position has not been publicly disclosed.
Quick Summary
The FDA is reportedly planning two new deputy commissioner roles in 2026. One position would oversee technology, healthcare and AI, while the other would focus on drugs. Jared Seehafer is reportedly the leading candidate for the technology role. The FDA has not formally announced either appointment, and final decisions remain pending.
FDA New Deputy Commissioner Roles 2026: Overview
The proposed leadership changes would create two separate areas of responsibility within the FDA:
| Proposed Role | Main Focus | Reported Status |
|---|---|---|
| Deputy Commissioner for Technology | Technology, healthcare and AI | Jared Seehafer reportedly the leading candidate |
| Deputy Commissioner for Drugs | Drug-related responsibilities | Candidate not publicly disclosed |
| Official appointment | Both positions | Not formally announced |
According to Reuters, the plans were reported by CNBC based on people familiar with the matter. The FDA has not yet made a formal announcement.
1. FDA Deputy Commissioner for Technology, Healthcare and AI
One proposed position would focus on technology, healthcare and artificial intelligence.
AI is becoming increasingly relevant to the healthcare and pharmaceutical industries. It can be used across areas such as:
- Drug discovery and development
- Clinical research
- Medical devices
- Healthcare data analysis
- Diagnostics
- Regulatory processes
According to the reported plans, Jared Seehafer is the leading candidate for the technology-focused role. However, this is a reported candidacy rather than a confirmed FDA appointment.
Why Is the FDA Focusing on AI and Technology?
The increasing use of AI in healthcare creates both opportunities and regulatory questions. FDA leadership will need to consider how emerging technologies should be evaluated, monitored and incorporated into healthcare and pharmaceutical processes.
A dedicated technology-focused leadership role could therefore give these issues greater attention within the agency.
2. FDA Deputy Commissioner for Drugs
The second proposed position would focus specifically on drugs and related responsibilities.
The reported plan does not publicly identify the candidate for this position.
A dedicated drugs-focused leadership role could place greater attention on areas such as:
- Pharmaceutical regulation
- Drug approval processes
- Regulatory review
- Drug safety and oversight
- Interactions with the pharmaceutical industry
However, the exact responsibilities of the proposed position have not been formally announced by the FDA.
Why Are the New FDA Deputy Commissioner Roles Important?
The proposed structure is significant because it separates two increasingly important areas: technology and AI and drug regulation.
For the pharmaceutical sector, FDA decisions can influence drug development, clinical research, regulatory submissions and market access.
At the same time, AI is becoming more important throughout the healthcare ecosystem. A senior FDA role dedicated to technology could potentially increase the agency’s focus on emerging technologies.
FDA Leadership Changes in 2026
The proposed deputy commissioner positions come during a broader period of leadership changes at the FDA.
President Donald Trump nominated Heidi Overton in August 2026 to lead the FDA. Her nomination still requires confirmation by the U.S. Senate.
Former FDA Commissioner Marty Makary resigned in May 2026 after approximately 13 months in the role. Following his resignation, Kyle Diamantas became acting FDA commissioner. The FDA’s official website currently lists Diamantas as Acting Commissioner of Food and Drugs.
Current FDA Leadership Status
| Position | Person | Status |
| FDA Commissioner | Heidi Overton | Nominated; Senate confirmation pending |
| Acting Commissioner | Kyle Diamantas | Currently serving as acting commissioner |
| Former Commissioner | Marty Makary | Resigned in May 2026 |
| Technology Deputy Commissioner | Jared Seehafer | Reported leading candidate; not confirmed |
| Drugs Deputy Commissioner | Not disclosed | No official appointment announced |
The status of these positions may change as the administration moves forward with its FDA leadership plans.
What Could the New FDA Structure Mean for the Pharmaceutical Industry?
If the reported plan is implemented, the new structure could affect how the FDA approaches both technology and pharmaceutical regulation.
For Pharmaceutical Companies
Companies may pay close attention to any changes in:
- Drug review processes
- Regulatory expectations
- FDA-industry interactions
- AI-related regulatory frameworks
- Drug approval policies
For Researchers
Researchers working in drug development, clinical trials, medical devices and healthcare technology may also be affected by future FDA policies.
For Pharmacists and Pharmacy Professionals
Pharmacists and pharmacy professionals can benefit from following FDA developments because changes in drug regulation may influence the pharmaceutical products, safety standards and regulatory policies they encounter in their professional careers.
Why Should Pharmacy Candidates Follow This FDA Update?
For B.Pharm, D.Pharm, M.Pharm students, pharmacists and pharmaceutical professionals, FDA developments can provide useful knowledge about international drug regulation and pharmaceutical policy.
This update is particularly relevant for candidates interested in:
- Drug Inspector careers
- Regulatory affairs
- Pharmaceutical industry jobs
- Clinical research
- Drug development
- Pharmacovigilance
- Medical affairs
- Government regulatory agencies
However, the proposed FDA positions are leadership appointments, not recruitment vacancies for pharmacy candidates. There is currently no information indicating that these positions are open to pharmacy students or Indian pharmacy job aspirants.
Are These FDA Positions Officially Confirmed?
No. The reported appointments have not been formally announced by the FDA, and no final decisions have been made, according to Reuters’ report.
Therefore, readers should not treat Jared Seehafer’s reported candidacy or the creation of the two roles as final until an official announcement is issued.
Important Details at a Glance
| Detail | Information |
| Organization | U.S. Food and Drug Administration (FDA) |
| Parent Department | U.S. Department of Health and Human Services (HHS) |
| Proposed positions | 2 Deputy Commissioner roles |
| Technology role | Technology, healthcare and AI |
| Drugs role | Drug-related responsibilities |
| Technology candidate | Jared Seehafer reportedly leading |
| Drugs candidate | Not publicly disclosed |
| Appointment status | Not officially announced |
| Final decision | Pending |
| FDA acting commissioner | Kyle Diamantas |
Important Dates
| Event | Date/Status |
| Report on proposed deputy commissioner roles | August 25, 2026 |
| Heidi Overton nominated to lead FDA | August 2026 |
| Marty Makary resigned | May 2026 |
| Formal appointment of new deputy commissioners | Not announced |
Important Links
- FDA Official Website: U.S. Food and Drug Administration
- FDA Commissioner Information: FDA Commissioner
- Source Report: Reuters report on the proposed FDA deputy commissioner positions. Reuters Report
FAQs About FDA New Deputy Commissioner Roles 2026
1. Is the FDA creating two new deputy commissioner positions in 2026?
According to reports, HHS is planning two new FDA deputy commissioner positions—one for technology, healthcare and AI, and another for drugs. The FDA has not formally announced the appointments.
2. Who is the reported candidate for the FDA technology role?
Jared Seehafer is reportedly the leading candidate for the technology-focused position. His appointment has not been formally confirmed.
3. Who will become the FDA Deputy Commissioner for Drugs?
The candidate for the proposed drugs-focused position has not been publicly disclosed, according to the report.
4. What would the FDA technology deputy commissioner oversee?
The proposed role would focus on technology, including healthcare and artificial intelligence. The exact responsibilities have not been formally announced.
5. Are the new FDA deputy commissioner appointments confirmed?
No. The appointments have not been formally announced, and no final decisions have been made.
6. Who is currently serving as acting FDA commissioner?
Kyle Diamantas is currently listed by the FDA as the Acting Commissioner of Food and Drugs.
7. Who was the previous FDA commissioner?
Marty Makary served as FDA commissioner before resigning in May 2026. Kyle Diamantas subsequently became acting commissioner.
8. Does this FDA update mean there are pharmacy jobs available?
No. The reported deputy commissioner positions are senior FDA leadership roles, not announced pharmacy recruitment vacancies. Pharmacy candidates should wait for an official FDA recruitment notification before considering any job application.
What Should Pharmacy Students and Pharma Professionals Watch Next?
The key developments to watch are:
- Official confirmation of the two deputy commissioner positions.
- The final candidate for the drugs-focused role.
- Whether Jared Seehafer is formally appointed to the technology role.
- The Senate confirmation process for Heidi Overton.
- Any changes to FDA policies involving AI, healthcare technology and drug regulation.
Because these appointments are still under consideration, the situation can change as new official information becomes available.
Conclusion
The FDA new deputy commissioner roles 2026 plan could reshape the agency’s leadership structure by creating separate senior positions for technology, healthcare and AI and drug-related responsibilities.
Jared Seehafer is reportedly the leading candidate for the technology role, while the candidate for the drugs position has not been disclosed. Importantly, neither appointment has been formally announced and no final decisions have been made.
For pharmacy students, pharmacists, pharmaceutical professionals and regulatory-affairs aspirants, this development is worth following because FDA leadership decisions can influence the future direction of drug regulation and healthcare technology.
Recommended Products
